Preemptive Pharmacogenomic Testing

Preemptive Pharmacogenomic Testing is a form of pharmacogenomic testing that involves the prospective genotyping of individuals for pharmacogenomic variants prior to the prescription of relevant medications, enabling future drug selection and dosing decisions based on genetic profile.

28

Publications

2K

Citations

347

Authors

113

Institutions

Publications per year

2017–2026

16

Authors

347

  1. PH
    Peter H. O’Donnell

    University of Chicago, United States

    3 publications · 162 citations

    3

    h-index

  2. CE
    Cyrine E. Haidar

    St. Jude Children's Research Hospital, United States

    3 publications · 308 citations

    3

    h-index

  3. JM
    James M. Hoffman

    St. Jude Children's Research Hospital, United States

    3 publications · 308 citations

    3

    h-index

  4. MJ
    Mark J. Ratain

    University of Chicago, United States

    3 publications · 162 citations

    3

    h-index

  5. KD
    Keith Danahey

    University of Chicago, United States

    3 publications · 162 citations

    3

    h-index

1–5 of 347

Venues

  1. Clinical Pharmacology & Therapeutics

    CPT · 9 publications · 929 citations

    9

    h-index

  2. Pharmacogenetics and Genomics

    2 publications · 56 citations

    2

    h-index

  3. Genetics in Medicine

    GIM · 2 publications · 146 citations

    2

    h-index

  4. 1

    h-index

  5. Value in Health

    1 publications · 63 citations

    1

    h-index

1–5